Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00099489
Other study ID # C-870
Secondary ID
Status Completed
Phase Phase 2
First received December 15, 2004
Last updated March 4, 2010
Start date February 2004
Est. completion date February 2006

Study information

Verified date March 2010
Source Biogen
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether AVONEX (Interferon Beta-1a), when compared to placebo, reduces the total dose of IVIg that is administered after Visit 5 and through Visit 9 (Week 32, End of Study).


Description:

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is an acquired peripheral neuropathy of unknown origin. The etiology is not well understood but is presumed to be immunological. Evidence for this comes from observed similarities to Guillain-Barre syndrome and from the favorable response with immunomodulatory treatments.

CIDP is a peripheral nervous system demyelinating neuropathy that is sometimes a corollary disorder to the central nervous system demyelination of multiple sclerosis (MS. The precise mechanisms underlying the pathogenesis are uncertain, but a number of those mechanisms support a potential role for immunomodulatory treatments such as interferon beta (e.g., Biogen Idec Inc.'s AVONEX).

The rationale for the use of AVONEX in CIDP derives from observations on the pathogenesis of the condition and its similarities to MS, the mechanism of action of AVONEX, clinical trials that have been performed in CIDP that support a role for IFN-beta, and the unmet need that currently exists because of availability and safety issues with existing therapies.

This Phase 2b study is a dose-ranging study designed to provide scientific evidence regarding the safety and efficacy of AVONEX in CIDP. In addition, the study aims to demonstrate the responsiveness and clinical relevance of changes in the MRC sum score and ODSS in CIDP patients.


Recruitment information / eligibility

Status Completed
Enrollment 67
Est. completion date February 2006
Est. primary completion date February 2006
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Written informed consent prior to any testing under this protocol

- Must be between 18 and 75 years of age

- Have a diagnosis of CIDP as determined by a board-certified or board-eligible neurologist, or equivalent, for at least 6 months, including fulfilling modified INCAT neurophysiological criteria for CIDP,CIDP motor deficit responsive to IVIg and alternative EP data that justifies subject inclusion, and/or supportive pathologic or laboratory data that supports the diagnosis of CIDP

- Documentation in the medical record prior to screening that the CIDP had been associated with loss of muscle strength, such that the MRC sum score was less than or equal to 58.

- Documentation in the medical record that the patient benefited fom IVIg treatment (patient had a 2-point change or equivalent in 60-point MRC sum score)

- Tested for IgM monoclonal gammopathy and found to have tested negative for IgM monoclonal gammopathy or if positive for IgM monoclonal gammopathy, then are MAG antibody-negative and proven to be IVI g responsive per protocol.

- Must have been clinically stable while on a constant regimen of IVIg (every 2-weeks, 3-weeks, 4-weeks or 5-weeks) in the 3 months prior to screening.

Exclusion Criteria*:

- Associated systemic disorder that might cause neuropathy.

- History of, or abnormal laboratory results indicative of any significant major disease or known drug hypersensitivity that, in the opinion of the investigator, would preclude the administration if IFN-beta or participation in this study.

- Subjects with diabetes mellitus will not be eligible, unless they satisfy both of the following requirements: a) their diabetes is well-controlled, with no retinopathy or nephropathy, having been identified during the ongoing care of their diabetes; and b) they have a normal sensory nerve action potential (SNAP) amplitude recorded in the sural nerve on at least one side of the body identified during electrophysiology (EP) testing documented in their medical record.

- Abnormal screening or baseline blood tests that the investigator deems clinically significant

- History of a seizure disorder prior to baseline (Visit 1, Week 0).

- History of suicidal ideation within 3 months prior to Baseline Visit (Week 0) or an episode of severe depression within 3 months prior to Baseline Visit (Week 0).

- Pure motor syndrome fulfilling criteria for multifocal motor neuropathy with conduction block.

- Pure sensory CIDP, or any other variant of CIDP without motor involvement

- Serious local infection or systemic infection within the 6 months prior to Screening.

- Use of IFN-beta at any time, use of plasma exchange, plasmapheresis, or any other immunosuppressant (with the exception of oral or non-systemic corticosteroids) within 6 months prior to Screening.

- History of intolerance to acetaminophen (paracetamol), ibuprofen, naproxen, and/or aspirin that would preclude use of at least one of these during the study.

- For female subjects, unless postmenopausal or surgically sterile, unwillingness to practice effective contraception, as defined by the Investigator, during the study.

- Female subjects considering becoming pregnant while in the study

- Female subjects who are currently pregnant or breast-feeding.

- This list is not exhaustive and there may be additional exclusions

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  • Polyradiculoneuropathy
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Intervention

Drug:
Interferon Beta-1a


Locations

Country Name City State
Australia St. Vincent's Hospital Fitzroy Victoria
Australia Liverpool Hospital Liverpool New South Wales
Australia Royal Melbourne Hospital Parkville Victoria
Australia Institute of Clinical Neurosciences Sydney New South Wales
Canada London Health Sciences Center London Ontario
Canada Montreal Neurological Hospital Montreal Quebec
United Kingdom Guy's Hospital/Dept. of Neuroimmunology London
United States Harvard University/MGH Boston Massachusetts
United States Tufts University/ St. Elizabeths Boston Massachusetts
United States University of Texas Southwestern Dallas Texas
United States University of Florida, Jacksonville Jacksonville Florida
United States University of Kansas Kansas City Kansas
United States University of Miami Miami Florida
United States University of Minnesota Minneapolis Minnesota
United States Louisiana State University New Orleans Louisiana
United States Weill Medical College of Cornell University New York New York
United States Phoenix Neurological Associates, Ltd. Phoenix Arizona
United States Raleigh Neurology Associates Raleigh North Carolina
United States University of Utah Salt Lake City Utah
United States Neuromuscular Research Center Scottsdale Arizona

Sponsors (1)

Lead Sponsor Collaborator
Biogen

Countries where clinical trial is conducted

United States,  Australia,  Canada,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary endpoint for the efficacy analyses is the total IVIg dose (g/Kg) administered after Visit 5 and through Visit 9 (Week 32, End of Study).
Secondary The time to disease progression.
Secondary Percentage reduction in IVIg dose (g/Kg).
Secondary The number of days between Visit 5 and either disease progression or Visit 9
Secondary (Week 32, End of Study).
Secondary The proportion of subjects with disease progression at Visit 9 (Week 32, End of Study).
Secondary The change in MRC sum score from baseline to the time of IVIg withdrawal.
Secondary Change from baseline to Visit 5 and to Visit 9 (Week 32, End of Study) in a composite score of maximal conduction velocity.
See also
  Status Clinical Trial Phase
Recruiting NCT04356781 - Do IgG Level Variations in CIDP and MMN Patients Following Initial Intravenous IVIg Treatment Correlate With Ultimate Dosing
Recruiting NCT04561557 - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System Early Phase 1
Terminated NCT01225276 - Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP Phase 2/Phase 3
Completed NCT02892890 - Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin N/A
Active, not recruiting NCT03584022 - Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial N/A
Terminated NCT02317562 - Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302 Phase 3
Recruiting NCT06325878 - Genetic Architecture of Chronic Inflammatory Demyelinating Polyradiculoneuropathy N/A
Recruiting NCT06290128 - A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work Phase 3
Completed NCT02293460 - Efficacy and Safety Study of I10E in Treatment of Patients With CIDP Phase 3
Completed NCT02017769 - MRI in Diagnosing and Monitoring CIDP N/A
Withdrawn NCT05257733 - Evaluation of the Diagnostic Contributions of Nerve Ultrasound in Chronic Inflammatory Demyelinating Polyneuropathy Associating Systemic Diseases (CIDP Echo-nerf)
Completed NCT03967899 - Study of Electrical Prognostic Factors of Response to Intravenous Immunoglobulin Treatment in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Not yet recruiting NCT04978623 - Role of High Frequency Ultrasound in Demyelinating Polyneuropathies
Active, not recruiting NCT02404298 - Transcriptome Analysis of the Peripheral Blood in CIDP N/A
Completed NCT01625182 - Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. Phase 3
Completed NCT02549170 - A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Phase 3
Completed NCT02955355 - Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP Phase 3
Active, not recruiting NCT04658472 - Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Phase 2
Withdrawn NCT04529291 - InertiaLocoGraphy as a Biomarker of Immunoglobulin Therapy Efficacy in Chronic Inflammatory Demyelinating Polyradiculoneuropathy N/A